The European Medicines Agency's Medicine Shortages Single Point of Contact (SPOC) Working Party, meeting on 16-17 March 2026, identified 14 new critical shortages and noted that 23 previously reported shortages remain unresolved, according to a meeting summary published on 4 May 2026. The group also flagged seasonal demand spikes for respiratory medicines as a risk for the upcoming winter, and endorsed operational recommendations to improve early detection and joint procurement, including shortening the mandatory reporting timeline for manufacturers from 60 to 30 days for products on the critical medicines list.
The SPOC Working Party, which brings together shortage focal points from all EU member states plus the European Commission and EMA, assessed the shortage landscape and discussed mitigation measures. The recommendations aim to balance faster regulatory intervention against the additional administrative burden on pharmaceutical companies, particularly small and medium-sized enterprises. The group also called for voluntary information sharing on production capacity.
Impact on stakeholders EU patients and healthcare providers could benefit from reduced shortage duration if the recommendations are implemented, improving access to essential treatments. However, the recommendations are non-binding, so actual impact depends on national implementation. Pharmaceutical manufacturers face increased compliance costs from shorter reporting deadlines, potentially requiring investment in real-time supply monitoring systems, with smaller firms particularly affected. National competent authorities may see improved crisis management through enhanced coordination and earlier warnings, but will need to allocate resources to process more frequent reports. EMA and the European Commission gain support for broader efforts to strengthen medicine supply security, though progress remains voluntary without binding legislation.
Expected institutional follow-up The SPOC Working Party's recommendations will be submitted to EMA's Executive Director and the European Commission for consideration. The Commission is expected to incorporate them into the ongoing revision of the pharmaceutical legislation, which includes provisions on shortage prevention and notification. The next SPOC meeting is scheduled for September 2026.
← Atlas › News › Health & Lifestyle